The university has received an $18.2 million award from the National Institutes of Health to establish one of 10 national centers to develop proteomic technologies for the diagnosis, understanding and improved treatment of heart, lung and blood disorders.

The National Heart, Lung and Blood Institute (NHLBI) Proteomics Center will bring together 21 Yale faculty from 12 departments and will build on the expertise of the Howard Hughes Medical Institute (HHMI) Biopolymer/Keck Laboratory at Yale University, one of the largest biotechnology laboratories of its kind in academia. The Proteomics Center is headed by Kenneth R. Williams, Ph.D., director of the HHMI/Keck Laboratory and professor (adjunct) of research in molecular biophysics and biochemistry. The center will focus on two technologies: proteome profiling and synthetic peptide-based reagents to block specific protein-protein interactions. The latter effort will be directed by the co-investigator on the NHLBI contract that established the center, William C. Sessa, Ph.D., director of the Yale Vascular Cell Signaling and Therapeutics Program and professor of pharmacology.

“By developing two complementary technologies in parallel, we hope to use protein profiling to identify key proteins involved in diseases of the heart, lung and blood and then develop novel reagents capable of specifically blocking the activities of those proteins,” Williams said. “The overall goal is to increase our understanding of the disease process, which should lead to more effective treatment.” Additional information and continuing updates on progress of research carried out in the Yale/NHLBI Proteomics Center may be found at http://info.med.yale.edu/ nhlbi-proteomics/.